CSBio CSBio

X
[{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck to Acquire Themis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Themis Bioscience"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APEIRON\u2019s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Apeiron Biologics"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marinomed Receives FFG Funding to Research SARS-Cov-2 Therapy Based On Carragelose\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Marinomed Biotech"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinomed Biotech Plans Clinical Trial with Carragelose Nasal Spray to Investigate Prevention of COVID-19 in Frontline Healthcare Staff","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Marinomed Biotech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Carragelose is a sulfated polymer from red seaweed and a unique, broadly active anti-viral compound. It is known as a gentle yet effective and safe prevention and treatment against respiratory infections.

            Lead Product(s): Carrageenan API

            Therapeutic Area: Infections and Infectious Diseases Product Name: Carragelose

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 20, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The planned acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform, and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate.

            Lead Product(s): SARS-CoV-2 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition May 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funding is directed towards a trial which will clinically test an inhalation solution with Carragelose® as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other respiratory viruses.

            Lead Product(s): Carragelose

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Austrian Research Promotion Agency

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding April 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The randomized, unblinded trial will treat 24 patients for seven days to obtain preliminary data on the impact of rhACE2 on biological, physiologic, and clinical outcomes and safety in patients.

            Lead Product(s): APN01

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY